Publication for BIRC5 and PTTG1

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	BIRC5	baculoviral IAP repeat containing 5	332			[link]
hsa	PTTG1	PTTG1 regulator of sister chromatid separation, securin	9232

Pubmed ID	Priority	Text
31423162	0.98	BIRC5, BUB1B, CCNB1, CCNB2, CDC20, CDK1, CDKN3, CENPF, CENPU, CKS2, CXCL10, DTL, GINS1, HMGB3, HN1, IGF1, KIAA0101, MAD2L1, MELK, NUSAP1, PBK, PRC1, PTTG1, RRM2, TK1, TOP2A, TPX2, TYMS, UBE2C, UBE2T, UHRF1, ZWINT) and considered to be the most relevant genes for breast cancer.
	0.97	BIRC5, BUB1B, CCNB1, CCNB2, CDC20, CDK1, CDKN3, CENPF, PRC1, PTTG1, TOP2A, TPX2, UBE2C and ZWINT) were present in MEblue.
	0.96	BIRC5), mitotic checkpoint serine/threonine-protein kinase BUB1beta (BUB1B), G2/mitotic-specific cyclin-B (CCNB)1, CCNB2, cell division cycle 20 (CDC20), cyclin-dependent kinase (CDK)1, CDK inhibitor 3 (CDKN3), centrosome protein F (CENPF), insulin-like growth factor 1 (IGF1), mitotic spindle assembly checkpoint protein MAD2A (MAD2L1), protein regulator of cytokinesis 1 (PRC1), pituitary tumor-transforming gene 1 protein (PTTG1), DNA topoisomerase 2alpha (TOP2A), targeting protein for Xklp2 (TPX2), ubiquitin-conjugating enzyme E2 C (UBE2C) and ZW10 interacting (ZWINT)] were considered hub genes and subjected to further analysis and validation.
	0.93	BIRC5, BUB1B, CCNB1, CCNB2, CDC20, CDK1, CDKN3, CENPF, PRC1, PTTG1, TOP2A, TPX2, UBE2C and ZWINT) that are closely associated with breast cancer were identified.
25157274	0.98	BIRC5, CENPF, PTTG1) were downregulated in response to BEV irrespective of the treatment period.
28542306	0.98	BIRC5, NUSAP1, CENPF, PRC1, ASPM, DTL), and 14 more CCP genes were upregulated in the MPNST vs. NF gene signature (FOXM1, TK1, CDC20, BUB1B, PBK, CDKN3, ASF1B, CEP55, DLGAP5, RAD51, KIF11, KIF20A, PTTG1, CDCA8).
26445238	0.97	PTTG1 expression in 328 newly diagnosed MM patients (E-GEOD-19784) plotted against expression of cell cycle-related genes CDK1 (a), CCNB1 (b), CCNB2 (c), BIRC5 (d), RRM2 (e) and the non-cell cycle gene DEPCD1 (f).
	0.97	Birc5, Cdk1, Rrm2 and Depcd1 was quantitated in 5TGM1-PTTG-kd cells compared with 5TGM1-SCRAM controls by qRT-PCR.
	0.97	Birc5 (survivin), which were among the most highly up-regulated genes identified in our patient analysis, were down-regulated by approximately 50 % by Pttg1 knockdown in the 5TGM1 cells.
	0.97	BIRC5 in PTTG1-mediated tumour growth.
	0.96	PTTG1 expression exhibited increased expression of cell proliferation-associated genes including CCNB1, CCNB2, CDK1, AURKA, BIRC5 and DEPDC1.
	0.96	Pttg1 in 5TGM1 cells decreased cellular proliferation, without affecting cell cycle distribution or viability, and decreased expression of Ccnb1, Birc5 and Depdc1 in vitro.
	0.96	PTTG1, CCNB1 and BIRC5 expression are under tight transcriptional control during cell cycle progression, being switched on during G2/M phase.
	0.93	Birc5 expression following Pttg1 could be a consequence of a decrease in G2/M phase cells, we saw no change in cell cycle distribution in the PTTG1-kd cells to support this.
	0.86	PTTG1 expression in this study, including CDK1, CCNB1, CCNB2 and BIRC5 are known to be inhibited downstream of p53; p53-mediated regulation of gene expression down stream of PTTG1 could be a focus of future studies.
24942023	0.97	BIRC5, HRK), DNA repair (PTTG1, UBE2V1), and drug resistance (TYMS, RAB5C).
29203780	0.97	PTTG1, CDC20 and BIRC5 were upregulated in accordance to the differential expression of 50 genes used in the Prosigna breast cancer gene signature assay (PAM50).
31422942	0.95	PTTG1, RRM2, TOP2A, UHRF1, CEP55, BIRC5, UBE2C, FOXM1 and CDC20 indicated excellent diagnostic efficiency for tumor and normal tissues (Figure 8).
	0.82	BIRC5, CDC20, CEP55, FOXM1, PTTG1, RRM2, TOP2A, UBE2C and UHRF1.
	0.64	PTTG1, RRM2, TOP2A, UHRF1, CEP55, BIRC5, UBE2C, FOXM1 and CDC20 are significantly upregulated in ccRCC compared with normal tissues (P < 0.01).
	0.64	PTTG1, (B) RRM2, (C) TOP2A, (D) UHRF1, (E) CEP55, (F) BIRC5, (G) UBE2C, (H) FOXM1, (I) CDC20.
30719129	0.95	BIRC5 (P= 2.01E-05), RRM2 (P=0.00396), MCM2 (P=0.000681), PTTG1 (P=0.00462), CDKN2A (P=0.00887), NEK2 (P=0.000828), CENPF (P=0.0304), CDCA5 (P=7.72E-05), RACGAP1 (P= 0.000754).
	0.94	BIRC5, RRM2, MCM2, PTTG1, CDKN2A, NEK2, CENPF, RACGAP1, CDCA5 and GNA14.
	0.61	BIRC5, RRM2, MCM2, PTTG1, CDKN2A, NEK2, CENPF, CDCA5 and RACGAP1.
27341628	0.95	BIRC5, CEP55, EXO1, KIF2C, MELK, MKI67, NDC80, PTTG1, UBE2C and UBE2T.
	0.57	PTTG1 and BIRC5.
32046048	0.91	BIRC5, RRM2, MCM2, PTTG1, CDKN2A, NEK2, CENPF, RACGAP1, GNA14, and CDCA5 are hub genes that may be important for diagnosis, clinical intervention, and prognosis of HCC.
16729057	0.90	BIRC5, kinesins), spindle checkpoint (BUB1, BUB1B, MAD2L1, CDC20), chromosome segregation (PTTG1, CENPF, ESPL1, UBE2C, PLK1, STK12), DNA packaging (HAT1, CHC1, SUV39H1, TOP2A), and chromosome organization (H1FX).
29871693	0.89	BIRC5 (AUC = 0.838), PTTG1 (AUC = 0.831), CCNA2 (AUC = 0.827), E2F1 (AUC = 0.826), KIF11 (AUC = 0.826), CDC25A (AUC = 0.823), UBE2C (AUC = 0.82), and CDK1 (AUC = 0.817) as the top 10 genes obtaining the best classification performance.
29190974	0.88	BIRC5, CCNB1, CDK1, CENPE, DLGAP5, KIF18A, KIF20A, NUF2, FOS, PTTG1, SPC24, TOP2A, and ZWINT displayed different levels of upregulation (P<0.05).
18570662	0.87	BIRC5, PTTG1, ATM, FOXO1A, TGFBR2, PRKAR1A, KLF5 and PDCD4 were identified through the microarray literature-based annotation search engine MILANO, suggesting these genes may be specifically involved in the promotion of the malignant conversion of nasopharyngeal epithelium.
	0.67	BIRC5 and ATM) have been documented in NPC associated articles, and the rest genes (PTTG1, FOXO1A, TGFBR2, PRKAR1A, CCND2, KLF5, and PDCD4) have never reported or poorly understood in NPC before.
17183660	0.87	PTTG1), and survival (baculoviral IAP repeat-containing 5, BIRC5, Figure 2A).
31771633	0.87	BIRC5, CENPE, ESPL1, PTTG1), and cell division (KIF11, CCNF, NUSAP1, CENPE, CDC20) have been found to be upregulated in pediatric B cell precursor ALL compared with normal B cell progenitors, highlighting their potential for use as therapeutic targets.
19662092	0.84	PTTG1, RFC4 and RFC5) and several other negative prognostic genes were common with our study (BIRC5/survivin, BUB1, CCNB1, CDC2, CENPA and MCM4), rendering the replicative system very important for future target development.
28109319	0.84	BIRC5 (Survivin), CXCL1, CXCL8 (IL8), E2F1, ETV4, EZH2, MMP1, MMP9, MYB, PTTG1, and YBX1.
31322260	0.83	BIRC5, AURKA, CCNB2, MAD2L1, HMMR, TTK, EZH2, CDC20, PTTG1, RACGAP1 and NCAPG (Table I).
29321820	0.80	BIRC5, EZH2, RACGAP1, PTTG1, and protein kinase, DNA-activated, catalytic polypeptide (PRKDC) are associated with E2F transcription factor cell cycle-related targets (p-value < 1.06 E-4).
	0.59	PTTG1, CENPF, BIRC5, Enhancer of zeste homolog 2 (EZH2), Rac GTPase activating protein 1 (RACGAP1), and cell division cycle 7 homolog (CDC7) are associated with G2M checkpoint (p-value < 3.16 E-6).
23704896	0.80	BIRC5, KIAA0101, SHCBP1, UBE2T, PTTG1, NUSAP1, DEPDC1, HELLS, CCNB1, KIF4A, and RRM2, that may be involved in tumorigenesis and in the processes of invasion and progression of disease.
29844366	0.75	BIRC5, LMNB1, POLA2, DEPDC1, MCM2, CDK1, PTTG1, CDC20, PLK1, KPNA2 and AURKA) that are overexpressed in E2F high PDX and 13 mRNA (RHBDL2, DLEU7-AS1, TMEM63A, IGSF9, NEIL1, BDKRB2, PDZK1IP1, ERN2, CTSE, VSIG2, BCL2L15, LOC100505633 and TXNIP) that were, on the contrary, down-regulated in the same PDX were selected (for each transcript the raw p-values were < 0.002, FDR adjusted p-values < 0.05, t-test score > 6 and <=-6 and the fold change were >1.2 and <=-1.2)(see Supplementary Figure 4).
31612029	0.68	BIRC5, (E) GAPDH, (F) CKS1B, (G) MCM6, (H) EZH2, (I) PTTG1, (J) CDK4, (K) TPX2, (L) PRC1, (M) CKS2, (N) CDC45, (O) KPNA2, (P) NCAPG and (Q) UBE2S.
28649643	0.62	BIRC5, BUB1B, CCNB1, and PTTG1 (Table 4); could classify patients in the validation cohort as low-risk or high-risk (HRhigh = 3.01, 95% CI 2.27-4.0, p = 1.81 x 10-14).